Risk Stratification and New Early Prevention and Treatment Strategies for Patients With Cardiomyopathy (STRENGTH）

Recruiting

• Conditions: Cardiomyopathies
• Interventions: Biological: Diagnosis of HCM; Biological: Diagnosis of ARVC; Biological: Diagnosis of NDLVC; Biological: Diagnosis of DCM; Biological: Diagnosis of RCM; Biological: Diagnosis of LVNC

• Registration Number: NCT06352320
• Lead Sponsor: First Affiliated Hospital Xi'an Jiaotong University

Brief Summary

This study will include patients with different types of cardiomyopathy from multiple centers were prospectively enrolled in a retrospective study to establish a natural population cohort of cardiomyopathy patients. By collecting clinical data and biological samples from surgical patients, we will construct a prognostic system for cardiomyopathy, optimize risk stratification, explore new strategies for the early prevention and treatment of cardiomyopathy, and improve the efficiency of clinical cardiomyopathy patients' diagnosis and treatment.

Detailed Description

This study will include patients with different types of cardiomyopathy from multiple centers were prospectively enrolled in a retrospective study to establish a natural population cohort of cardiomyopathy patients. By collecting clinical data and biological samples from surgical patients, we will construct a prognostic system for cardiomyopathy, optimize risk stratification, explore new strategies for the early prevention and treatment of cardiomyopathy, and improve the efficiency of clinical cardiomyopathy patients' diagnosis and treatment.

Study Timeline

• Status Verified: 2024-03
• Study First Submitted: 2024-04-02
• Study First Submitted QC: 2024-04-02
• Study First Posted: 2024-04-08
• Study Start: 2024-05-09
• Last Update Submitted: 2024-07-10
• Last Update Posted: 2024-07-12
• Primary Completion: 2030-08-31
• Study Completion: 2032-08-31

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 500

Inclusion Criteria

• Age >18 years old.
• The diagnosis of cardiomyopathy was confirmed by cardiac ultrasound, electrocardiogram, magnetic resonance angiography, pathological examination and gene sequencing.
• Patients or their families agreed to participate in the study and authorized informed consent.

Exclusion Criteria

• Incomplete clinical data.
• Do not agree to the inclusion or refuse to authorize the informed consent.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
HCM group	Diagnosis of HCM	Patients were diagnosed with HCM.
ARVC group	Diagnosis of ARVC	Patients were diagnosed with ARVC.
NDLVC group	Diagnosis of NDLVC	Patients were diagnosed with NDLVC.
DCM group	Diagnosis of DCM	Patients were diagnosed with DCM.
RCM group	Diagnosis of RCM	Patients were diagnosed with RCM.
LVNC group	Diagnosis of LVNC	Patients were diagnosed with LNVC.

Primary Outcome Measures

Name	Time	Method
Change in the incidence of mortality rate	At diagnosis, before discharge (about 7 days), 1, 3, 6, 9 month, 1, 2, 3, 5, 10 year.	The survival status will be obtained from the medical records and phone calls to patients or their family members

Trial Locations

Locations (1)

First Affiliated Hospital of Xi'an Jiantong University; 🇨🇳 Xi'an, Shaanxi, China